Scarica l'app Stockscreener
17.83
1.31%
0.23
Dopo l'orario di chiusura:
18.09
0.26
+1.46%
Precedente Chiudi:
$17.60
Aprire:
$17.63
Volume 24 ore:
184.54K
Relative Volume:
0.96
Capitalizzazione di mercato:
$954.45M
Reddito:
Utile/perdita netta:
Rapporto P/E:
-24.77
EPS:
-0.7198
Flusso di cassa netto:
1 W Prestazione:
-1.76%
1M Prestazione:
-19.47%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.14
$18.00
Intervallo di 1 settimana:
$15.79
$18.14
Portata 52W:
$14.85
$28.38
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Nome
Seaport Therapeutics Inc
Settore
Industria
Telefono
617-807-4062
Indirizzo
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
17.83 | 954.45M | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seaport Therapeutics Inc Stock (SPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-14 | Iniziato | Canaccord Genuity | Buy |
| 2026-09-25 | Iniziato | Raymond James | Strong Buy |
| 2026-07-15 | Iniziato | H.C. Wainwright | Buy |
| 2026-05-26 | Iniziato | Citigroup | Buy |
| 2026-05-26 | Iniziato | JP Morgan | Overweight |
| 2026-05-26 | Iniziato | Leerink Partners | Outperform |
| 2026-05-26 | Iniziato | Stifel | Buy |
Mostra tutto
Seaport Therapeutics Inc Borsa (SPTX) Ultime notizie
Seaport reports 6.8-fold GlyphAgo bioavailability increase - grafa.com
Seaport Therapeutics (NASDAQ:SPTX) Shares Up 3.6%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpWhat's Next? - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Stock Has Consensus Target Price of $38.57 - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 6.3%Here's What Happened - MarketBeat
Seaport Therapeutics, Inc. $SPTX Shares Newly Acquired by State Street Corp - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Shares Gap UpHere's Why - MarketBeat
Raymond James initiates Seaport Therapeutics stock coverage with strong buy on depression drug potential - Investing.com
Seaport Therapeutics, Inc. (SPTX) stock price, news, quote and history - uk.finance.yahoo.com
The Manufacturers Life Insurance Company Acquires New Stake in Seaport Therapeutics, Inc. $SPTX - marketbeat.com
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Analysts Conflicted on These NA Names: SailPoint, Inc. (SAIL) and Seaport Therapeutics, Inc. (SPTX) - theglobeandmail.com
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 4.6%Should You Buy? - MarketBeat
HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX) - MarketBeat
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - biospace.com
Seaport Therapeutics at citigroup’s biopharma back to school summit 2026: platform push - Investing.com Canada
Seaport Therapeutics reports positive phase 1 trial results - investing.com
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com Canada
PureTech Says Seaport Therapeutics Reports Positive Phase 1 Driving Trial Results for GlyphAllo - TradingView
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics reports positive phase 1 trial results By Investing.com - Investing.com UK
RCSPureTech Health PLCPRTC's SPTX: New Positive Phase 1 GlyphAllo Data - TradingView
Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial - marketscreener.com
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Business Wire
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers - Yahoo Finance
A 375 mg dose did not impair next-morning driving in a Seaport trial - Stock Titan
Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts - marketbeat.com
Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - BioSpace
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - Yahoo Finance UK
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference - Yahoo Finance
Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2%Here's Why - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighHere's Why - MarketBeat
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO - 24/7 Wall St.
Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Selvaraju Reiterates Buy on Seaport, Citing Differentiated Neuropsychiatry Pipeline and Unchanged $50 Price Target - TipRanks
Trv Gp Vi LLC Acquires New Shares in Seaport Therapeutics, Inc. $SPTX - MarketBeat
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Stifel Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.com.au
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics Inc Azioni (SPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Seaport Therapeutics Inc Azioni (SPTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC | 10% Owner |
May 04 '26 |
Buy |
18.00 |
1,100,000 |
19,800,000 |
6,294,951 |
4.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):